购物车
- 全部删除
- 您的购物车当前为空
Etripamil (MSP-2017) 是一种短效L 型钙通道拮抗剂,可用于治疗阵发性室上性心动过速的研究。它通过抑制房室结细胞中钙慢通道的钙离子流入,显示房室结传导并延长房室结不应期
为众多的药物研发团队赋能,
让新药发现更简单!
Etripamil (MSP-2017) 是一种短效L 型钙通道拮抗剂,可用于治疗阵发性室上性心动过速的研究。它通过抑制房室结细胞中钙慢通道的钙离子流入,显示房室结传导并延长房室结不应期
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 689 | 现货 | |
5 mg | ¥ 1,820 | 现货 | |
10 mg | ¥ 2,880 | 现货 | |
25 mg | ¥ 4,690 | 现货 | |
50 mg | ¥ 6,570 | 现货 | |
100 mg | ¥ 8,860 | 现货 | |
200 mg | ¥ 11,900 | 现货 |
产品描述 | Etripamil (MSP-2017) displays atrioventricular nodal conduction and prolongs atrioventricular nodal refractory periods by inhibiting calcium ion influx through the calcium slow channels in the atrioventricular node cells. Etripamil is an antagonist of short-acting L-type calcium-channel. It has a rapid onset of action designed for intranasal administration. It is also used to treat Paroxysmal Supraventricular Tachycardia. |
体外活性 | Etripamil通过抑制心房室结细胞中的钙缓慢通道中的钙离子流入,显示心房室结传导并延长心房室结不应期。 |
别名 | MSP-2017, (-)-MSP-2017 |
分子量 | 452.59 |
分子式 | C27H36N2O4 |
CAS No. | 1593673-23-4 |
Smiles | COC(=O)c1cccc(CCN(C)CCC[C@](C#N)(C(C)C)c2ccc(OC)c(OC)c2)c1 |
密度 | 1.079 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | Ethanol: 110 mg/mL (243.05 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
Ethanol
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容